On June 5, 2024, Denis Chetverikov took part in the 27th St. Petersburg International Economic Forum (SPIEF). The President spoke as part of a panel discussion on issues of consumer confidence in domestic pharmaceutical products.

During his speech, Denis shared the results of a recent AKRIKHIN study conducted among 1,200 patients throughout Russia.

According to the study, 27% of Russians give preference to domestic drugs when purchasing medicines, and more than half of respondents (56%) trust both Russian and foreign manufacturers equally.

The President emphasized the importance of increasing patient confidence in generic drugs, which are the basis of the Russian pharmaceutical industry, emphasizing that in terms of quality and effectiveness they are not inferior to original drugs.

During his speech, Denis Chetverikov raised the issue of the impact of evergreen patenting on budget savings for healthcare, pointing to the practice of foreign companies issuing so-called “secondary patents”, which actually limits the development of the country’s pharmaceutical market.

June 6, 2024 The President of the AKRIKHIN company took part in a round table together with the Minister of Industry and Trade Anton Alikhanov and the Minister of Health Mikhail Murashko. The round table was devoted to the issue of labeling and its role in strengthening the potential of domestic business.

Denis Chetverikov emphasized that the high quality of data obtained from MDLP provides unique opportunities for analysis. He noted that the company successfully uses the information obtained through Honest Sign to forecast production processes and build up inventories of raw materials.

“The labeling system gives us data at a completely new level of quality. We are now able to track in real time the outflow of goods from pharmacies, their inflow into pharmacies, as well as the quantity of goods for each accounting unit, and this data is used to forecast our production.”

In addition, the President additionally noted the desire of pharmaceutical manufacturers to receive syndicated sales data of the entire pharmaceutical market to conduct better analytics.

Video broadcast of the “Medicine Safety” forum